![Eric Schlumpf](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Eric Schlumpf
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Stuart Therapeutics LLC
![]() Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Directeur/Bestuurslid | 01-01-2018 | - |
Algemeen Directeur | 01-01-2018 | - | |
Oprichter | 01-01-2018 | - | |
President | 01-01-2018 | - |
Loopbaan van Eric Schlumpf
Statistieken
Internationaal
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Sectoraal
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Stuart Therapeutics LLC
![]() Stuart Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Stuart Therapeutics LLC, founded in 2017, is a company based in Stuart, FL that specializes in the development of ECM-targeting therapeutics for disease treatment. Stuart Therapeutics has conducted extensive research in a variety of anterior and posterior segment ophthalmic disease indications, demonstrating rapid effects in treated tissues. The company's patented platform technology, PolyCol™, is a portfolio of synthesized collagen mimetic peptides designed to repair disease or injury-damaged helical collagen structures. This repair results in a restoration of homeostatic cell signaling, positively affecting cell growth and proliferation while reducing inflammation. The company was founded in 2018 by Eric Schlumpf, who has been the CEO since then. | Commercial Services |
- Beurs
- Insiders
- Eric Schlumpf
- Ervaring